{"protocolSection":{"identificationModule":{"nctId":"NCT01558271","orgStudyIdInfo":{"id":"13990"},"secondaryIdInfos":[{"id":"H9X-JE-GBDP","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus","officialTitle":"A Phase 3 Study of LY2189265 Monotherapy Compared to Placebo and Liraglutide in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"statusVerifiedDate":"2015-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2012-03"},"primaryCompletionDateStruct":{"date":"2013-10","type":"ACTUAL"},"completionDateStruct":{"date":"2014-05","type":"ACTUAL"},"studyFirstSubmitDate":"2012-03-12","studyFirstSubmitQcDate":"2012-03-16","studyFirstPostDateStruct":{"date":"2012-03-20","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-10-22","resultsFirstSubmitQcDate":"2014-10-22","resultsFirstPostDateStruct":{"date":"2014-10-30","type":"ESTIMATED"},"dispFirstSubmitDate":"2014-04-25","dispFirstSubmitQcDate":"2014-04-25","dispFirstPostDateStruct":{"date":"2014-05-13","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-05-20","lastUpdatePostDateStruct":{"date":"2015-05-22","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 in participants with type 2 diabetes mellitus who are not taking oral antidiabetic medication.","detailedDescription":"Rescue therapy (defined as alternative antihyperglycemic medication use or dose modification of oral antihyperglycemic medication \\[OAM\\]) may have been initiated during the planned treatment period if the participant discontinued study drug or met prespecified thresholds for severe, persistent hyperglycemia. Efficacy data, as well as data for hypoglycemic episodes from participants who permanently discontinued study treatment but switched to another diabetes medication and remained in the study, were censored from the point of initiating new treatment onwards."},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"],"keywords":["GLP-1"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":492,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"LY2189265","type":"EXPERIMENTAL","description":"Once-weekly subcutaneous (SC) injection of 0.75 milligrams (mg) of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.","interventionNames":["Drug: LY2189265"]},{"label":"Placebo/LY2189265","type":"PLACEBO_COMPARATOR","description":"Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.","interventionNames":["Drug: LY2189265","Drug: Placebo"]},{"label":"Liraglutide","type":"ACTIVE_COMPARATOR","description":"Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy.","interventionNames":["Drug: Liraglutide"]}],"interventions":[{"type":"DRUG","name":"LY2189265","armGroupLabels":["LY2189265","Placebo/LY2189265"],"otherNames":["Dulaglutide"]},{"type":"DRUG","name":"Placebo","armGroupLabels":["Placebo/LY2189265"]},{"type":"DRUG","name":"Liraglutide","armGroupLabels":["Liraglutide"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks","description":"Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, visit, treatment-by-visit, prestudy therapy (oral antihyperglycemic medication \\[OAM\\] yes/no), baseline body mass index (BMI) group (\\<25 or \\>=25 kilograms per meter squared \\[kg/m\\^2\\]) as fixed effects, baseline HbA1c as a covariate, and participant as a random effect.","timeFrame":"Baseline, 26 weeks"}],"secondaryOutcomes":[{"measure":"Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 52 Weeks","description":"LS means were calculated using MMRM analysis with treatment, visit, treatment-by-visit, prestudy therapy (OAM yes/no), baseline BMI group (\\<25 or \\>=25 kg/m\\^2) as fixed effects, baseline HbA1c as a covariate, and participant as a random effect.","timeFrame":"Baseline, 52 weeks"},{"measure":"Percentage of Participants Who Achieved HbA1c <=6.5% or <7%","description":"The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% at Week 26 and Week 52 was analyzed with a Cochran-Mantel-Haenszel test stratified by prestudy therapy (OAM yes/no) and baseline BMI group (\\<25 or \\>=25 kg/m\\^2).","timeFrame":"Up to 26 and 52 weeks"},{"measure":"Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks and 52 Weeks","description":"LS means were calculated using MMRM analysis with treatment, visit, treatment-by-visit, prestudy therapy (OAM yes/no), baseline BMI group (\\<25 or \\>=25 kg/m\\^2) as fixed effects, baseline FBG as a covariate, and participant as a random effect.","timeFrame":"Baseline, 26 weeks, 52 weeks"},{"measure":"Change From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) at 26 Weeks and 52 Weeks","description":"Participants were to test and record SMBG concentrations in their study diaries before each meal (breakfast, lunch, and dinner), approximately 2 hours after the start of each meal, and at bedtime. LS means were calculated using analysis of covariance (ANCOVA) model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\\<25 or \\>=25 kg/m\\^2) as fixed effects and baseline SMBG as a covariate.","timeFrame":"Baseline, 26 weeks, 52 weeks"},{"measure":"Change From Baseline in Body Weight at 26 Weeks and 52 Weeks","description":"LS means were calculated using MMRM analysis with treatment, visit, treatment-by-visit, prestudy therapy (OAM yes/no), baseline BMI group (\\<25 or \\>=25 kg/m\\^2) as fixed effects, baseline body weight as a covariate, and participant as a random effect.","timeFrame":"Baseline, 26 weeks, 52 weeks"},{"measure":"Change From Baseline in Insulin Sensitivity Using Updated Homeostasis Model Assessment (HOMA 2) at 26 Weeks and 52 Weeks","description":"HOMA 2 quantifies insulin resistance and beta-cell function. HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. Change in insulin sensitivity was assessed based on change from baseline of HOMA2-%S using fasting insulin (FI) and fasting C-peptide (FCP). LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\\<25 or \\>=25 kg/m\\^2) as fixed effects and baseline HOMA2-%S as a covariate.","timeFrame":"Baseline, 26 weeks, 52 weeks"},{"measure":"Change From Baseline in Beta-cell Function Using Updated Homeostasis Model Assessment (HOMA 2) at 26 Weeks and 52 Weeks","description":"HOMA 2 quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta-cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. Change in beta-cell function was assessed based on change from baseline of HOMA2-%B using fasting insulin (FI) and fasting C-peptide (FCP). LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\\<25 or \\>=25 kg/m\\^2) as fixed effects and baseline HOMA2-%B as a covariate.","timeFrame":"Baseline, 26 weeks, 52 weeks"},{"measure":"Percentage of Participants With Hypoglycemic Episodes","description":"The percentage of participants with hypoglycemic episodes was calculated by dividing the number of participants with at least one hypoglycemic episode over the 26-week or 52-week treatment period by the total number of participants analyzed, multiplied by 100%. All classifications of hypoglycemia (documented symptomatic, asymptomatic, severe, nocturnal, non-nocturnal, probable symptomatic, relative, and unspecified) were included, except for episodes of relative hypoglycemia that were not severe. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","timeFrame":"Baseline through 26 weeks and Baseline through 52 weeks"},{"measure":"30-Day Rate of Hypoglycemic Episodes","description":"The 30-day total hypoglycemia rate over 26 weeks and 52 weeks of treatment is summarized. All classifications of hypoglycemia (documented symptomatic, asymptomatic, severe, nocturnal, non-nocturnal, probable symptomatic, relative, and unspecified) were included, except for episodes of relative hypoglycemia that were not severe. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","timeFrame":"Baseline through 26 weeks and Baseline through 52 weeks"},{"measure":"Number of Participants With Adjudicated Cardiovascular Events at 26 Weeks and 52 Weeks","description":"Deaths and nonfatal cardiovascular adverse events were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular events subjected to adjudication included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","timeFrame":"Baseline through 26 weeks and Baseline through 52 weeks"},{"measure":"Change From Baseline in Pulse Rate at 26 Weeks and 52 Weeks","description":"Sitting pulse rate was measured. LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\\<25 or \\>=25 kg/m\\^2) as fixed effects and baseline pulse rate as a covariate.","timeFrame":"Baseline, 26 weeks, 52 weeks"},{"measure":"Change From Baseline in Blood Pressure at 26 Weeks and 52 Weeks","description":"Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\\<25 or \\>=25 kg/m\\^2) as fixed effects and baseline blood pressure as a covariate.","timeFrame":"Baseline, 26 weeks, 52 weeks"},{"measure":"Number of Participants With Adjudicated Pancreatitis at 26 Weeks and 52 Weeks","description":"Events of pancreatitis (including suspected pancreatitis and severe or serious abdominal pain) were adjudicated by a committee of expert physicians external to the Sponsor. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","timeFrame":"Baseline through 26 weeks and Baseline through 52 weeks"},{"measure":"Change From Baseline in Pancreatic Enzymes at 26 Weeks and 52 Weeks","description":"Pancreatic enzyme (lipase and total amylase) concentrations were measured.","timeFrame":"Baseline, 26 weeks, 52 weeks"},{"measure":"Change From Baseline in Serum Calcitonin at 26 Weeks and 52 Weeks","timeFrame":"Baseline, 26 weeks, 52 weeks"},{"measure":"Number of Participants With Treatment-Emergent LY2189265 Anti-Drug Antibodies (ADAs) at 26 Weeks and 52 Weeks","description":"A participant was considered to have treatment-emergent LY2189265 ADAs if the participant had at least 1 titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from the baseline measurement.","timeFrame":"Baseline through 26 weeks and Baseline through 52 weeks"},{"measure":"Number of Participants Requiring Additional Intervention Due to Hyperglycemia at 26 Weeks and 52 Weeks","description":"Additional intervention was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. The number of participants requiring additional intervention due to hyperglycemia is summarized cumulatively at 26 and 52 weeks.","timeFrame":"Baseline through 26 weeks and Baseline through 52 weeks"},{"measure":"Change From Baseline in Electrocardiogram Parameters at 26 Weeks and 52 Weeks","description":"Fridericia Corrected QT (QTcF) Interval and PR Interval are summarized. The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTcF = QT/RR\\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. LS means were calculated using ANCOVA model with treatment as a fixed effect and the baseline ECG parameter as the covariate.","timeFrame":"Baseline, 26 weeks, 52 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants who have had a diagnosis of type 2 diabetes mellitus before screening.\n* Participants who have been Oral Antihyperglycemic Medication (OAM)-naïve (diet and exercise only) or been taking OAM monotherapy except for thiazolidinedione (TZD) and are willing to discontinue this medication. Participants taking OAM monotherapy must complete 8-week washout period prior to randomization.\n* Participants who are OAM naïve with a screening glycosylated hemoglobin (HbA1c) value of 7.0% to 10.0% and randomization HbA1c value of 7.0% to 10.0%, or who are taking OAM monotherapy with screening HbA1c value of 6.5% to 9.0% and randomization HbA1c value of 7.0% to 10.0%.\n* Participants who have a body mass index (BMI) of 18.5 kilograms per meter squared (kg/m\\^2) to 35.0 kg/m\\^2.\n\nExclusion Criteria:\n\n* Participants who have a diagnosis of type 1 diabetes.\n* Participants who have previously been treated with any other glucagon-like peptide-1 (GLP-1) analog.\n* Participants who have been receiving more than half of the maximum dose of sulfonylureas at screening.\n* Participants who have been currently taking insulin or TZD, or have had previous insulin or TZD treatment within 3 months before screening.\n* Participants who have obvious clinical signs or symptoms of pancreatitis, a history of chronic pancreatitis or acute pancreatitis at screening, as determined by the investigator. Participants who have a serum amylase concentration ≥3 times the upper limit of the reference range and/or a serum lipase concentration ≥2 times the upper limit of the reference range, as determined by the central laboratory at screening.\n* Participants who have self or family history of medullary C-cell hyperplasia, focal hyperplasia, or medullary thyroid carcinoma (MTC).","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fukuoka","zip":"819-0168","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hokkaido","zip":"060-8604","country":"Japan"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hyōgo","zip":"663-8501","country":"Japan","geoPoint":{"lat":43.36667,"lon":144.43333}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ibaraki","zip":"302-0118","country":"Japan","geoPoint":{"lat":34.81641,"lon":135.56828}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ishikawa","zip":"920-8641","country":"Japan","geoPoint":{"lat":26.42333,"lon":127.82139}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kanagawa","zip":"235-0045","country":"Japan","geoPoint":{"lat":37.58333,"lon":139.91667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kumamoto","zip":"862-0976","country":"Japan","geoPoint":{"lat":32.80589,"lon":130.69181}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Miyagi","zip":"980-0021","country":"Japan","geoPoint":{"lat":26.62566,"lon":128.18236}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Nagano","zip":"399-0006","country":"Japan","geoPoint":{"lat":36.65,"lon":138.18333}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Osaka","zip":"532-0003","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tokyo","zip":"160-0022","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Toyama","zip":"939-0363","country":"Japan","geoPoint":{"lat":36.7,"lon":137.21667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Yamaguchi","zip":"756-0095","country":"Japan","geoPoint":{"lat":34.18333,"lon":131.46667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Yokohama","zip":"220-0012","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}}]},"referencesModule":{"references":[{"pmid":"29264713","type":"DERIVED","citation":"Iwamoto N, Matsui A, Kazama H, Oura T. Subgroup Analysis Stratified by Baseline Pancreatic beta-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 Diabetes. Diabetes Ther. 2018 Feb;9(1):383-394. doi: 10.1007/s13300-017-0346-4. Epub 2017 Dec 20."},{"pmid":"28606095","type":"DERIVED","citation":"Suzuki S, Oura T, Takeuchi M, Boye KS. Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies. Health Qual Life Outcomes. 2017 Jun 12;15(1):123. doi: 10.1186/s12955-017-0696-7."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"LY2189265","description":"Once-weekly subcutaneous (SC) injection of 0.75 milligrams (mg) of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"FG001","title":"Placebo/LY2189265","description":"Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"FG002","title":"Liraglutide","description":"Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"281"},{"groupId":"FG001","numSubjects":"70"},{"groupId":"FG002","numSubjects":"141"}]},{"type":"Received at Least 1 Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"280"},{"groupId":"FG001","numSubjects":"70"},{"groupId":"FG002","numSubjects":"137"}]},{"type":"Completed 26 Weeks","achievements":[{"groupId":"FG000","numSubjects":"271"},{"groupId":"FG001","numSubjects":"63"},{"groupId":"FG002","numSubjects":"128"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"263"},{"groupId":"FG001","numSubjects":"59"},{"groupId":"FG002","numSubjects":"124"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"11"},{"groupId":"FG002","numSubjects":"17"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"12"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Participants who received at least 1 dose of study medication.","groups":[{"id":"BG000","title":"LY2189265","description":"Once-weekly SC injection of 0.75 mg of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"BG001","title":"Placebo/LY2189265","description":"Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"BG002","title":"Liraglutide","description":"Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"280"},{"groupId":"BG001","value":"70"},{"groupId":"BG002","value":"137"},{"groupId":"BG003","value":"487"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"57.15","spread":"9.57"},{"groupId":"BG001","value":"57.66","spread":"8.34"},{"groupId":"BG002","value":"57.91","spread":"10.93"},{"groupId":"BG003","value":"57.44","spread":"9.63"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"52"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"91"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"228"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"113"},{"groupId":"BG003","value":"396"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"280"},{"groupId":"BG001","value":"70"},{"groupId":"BG002","value":"137"},{"groupId":"BG003","value":"487"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Japan","categories":[{"measurements":[{"groupId":"BG000","value":"280"},{"groupId":"BG001","value":"70"},{"groupId":"BG002","value":"137"},{"groupId":"BG003","value":"487"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks","description":"Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, visit, treatment-by-visit, prestudy therapy (oral antihyperglycemic medication \\[OAM\\] yes/no), baseline body mass index (BMI) group (\\<25 or \\>=25 kilograms per meter squared \\[kg/m\\^2\\]) as fixed effects, baseline HbA1c as a covariate, and participant as a random effect.","populationDescription":"Participants who received at least one dose of study medication with evaluable HbA1c data. Only pre-rescue measurements were used.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percentage of HbA1c","timeFrame":"Baseline, 26 weeks","groups":[{"id":"OG000","title":"LY2189265","description":"Once-weekly SC injection of 0.75 mg of LY2189265 for 26 weeks of blinded therapy."},{"id":"OG001","title":"Placebo","description":"Once-weekly SC injection of placebo for 26 weeks of blinded therapy."},{"id":"OG002","title":"Liraglutide","description":"Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 24 weeks of open therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"280"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"136"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.43","spread":"0.05"},{"groupId":"OG001","value":"0.14","spread":"0.10"},{"groupId":"OG002","value":"-1.33","spread":"0.07"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Approximately 490 participants were to be randomized in a 4:1:2 ratio to LY2189265, placebo, or Liraglutide, respectively. This sample size would provide greater than 99% power to demonstrate superiority of LY2189265 to placebo. This computation assumed a true mean difference in HbA1c change from baseline between LY2189265 and placebo being 0.8%, a common standard deviation of 1.1%, a 1-sided significance level of 0.025, and a 9% drop-out rate between randomization and Week 26.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-1.57","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.79","ciUpperLimit":"-1.35"},{"groupIds":["OG000","OG002"],"groupDescription":"Approximately 490 participants were to be randomized in a 4:1:2 ratio to LY2189265, placebo, or Liraglutide, respectively. This sample size would provide \\>90% power to confirm non-inferiority of LY2189265 to liraglutide by a margin of 0.4%. This computation assumed a true mean difference in HbA1c change from baseline between LY2189265 and Liraglutide being 0%, a common standard deviation of 1.1%, a 1-sided significance level of 0.025, and a 9% drop-out rate between randomization and Week 26.","testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"If the upper limit of the 95% Confidence Interval (CI) was \\<0.4%, then LY2189265 was declared non-inferior to Liraglutide. If the upper limit of the 95% CI was \\<0.0%, then LY2189265 was declared superior to liraglutide.","pValue":"0.248","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-0.10","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.27","ciUpperLimit":"0.07"}]},{"type":"SECONDARY","title":"Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 52 Weeks","description":"LS means were calculated using MMRM analysis with treatment, visit, treatment-by-visit, prestudy therapy (OAM yes/no), baseline BMI group (\\<25 or \\>=25 kg/m\\^2) as fixed effects, baseline HbA1c as a covariate, and participant as a random effect.","populationDescription":"Participants who received at least one dose of study medication with evaluable HbA1c data. Only pre-rescue measurements were used.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percentage of HbA1c","timeFrame":"Baseline, 52 weeks","groups":[{"id":"OG000","title":"LY2189265","description":"Once-weekly SC injection of 0.75 mg of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG001","title":"Placebo/LY2189265","description":"Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG002","title":"Liraglutide","description":"Once-daily SC injection of 0.3 mg of Liraglutide for the first week followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"280"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"136"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.39","spread":"0.06"},{"groupId":"OG001","value":"-1.55","spread":"0.12"},{"groupId":"OG002","value":"-1.19","spread":"0.08"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.040","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-0.20","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.39","ciUpperLimit":"-0.01"}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved HbA1c <=6.5% or <7%","description":"The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% at Week 26 and Week 52 was analyzed with a Cochran-Mantel-Haenszel test stratified by prestudy therapy (OAM yes/no) and baseline BMI group (\\<25 or \\>=25 kg/m\\^2).","populationDescription":"Participants who were randomized and received at least one dose of study medication with evaluable HbA1c data. Only pre-rescue measurements were used. Missing endpoints were imputed with the last observation carried forward (LOCF), using only postbaseline data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Up to 26 and 52 weeks","groups":[{"id":"OG000","title":"LY2189265","description":"Once-weekly SC injection of 0.75 mg of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG001","title":"Placebo/LY2189265","description":"Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG002","title":"Liraglutide","description":"Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"280"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"136"}]}],"classes":[{"title":"HbA1c <7%, 26 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"71.4"},{"groupId":"OG001","value":"5.9"},{"groupId":"OG002","value":"69.1"}]}]},{"title":"HbA1c <=6.5%, 26 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"50.0"},{"groupId":"OG001","value":"1.5"},{"groupId":"OG002","value":"49.3"}]}]},{"title":"HbA1c <7%, 52 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"67.9"},{"groupId":"OG001","value":"70.6"},{"groupId":"OG002","value":"60.3"}]}]},{"title":"HbA1c <=6.5%, 52 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"49.3"},{"groupId":"OG001","value":"52.9"},{"groupId":"OG002","value":"41.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Treatment comparison for HbA1c \\<7% at 26 weeks between LY2189265 and placebo.","statisticalMethod":"Cochran-Mantel-Haenszel","statisticalComment":"Pairwise comparison was adjusted for prestudy therapy (OAM yes/no), baseline BMI group (\\<25 / \\>=25 kg/m\\^2), and baseline HbA1c group.","ciNumSides":"TWO_SIDED"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.608","pValueComment":"Treatment comparison for HbA1c \\<7% at 26 weeks between LY2189265 and Liraglutide.","statisticalMethod":"Cochran-Mantel-Haenszel","statisticalComment":"Pairwise comparison was adjusted for prestudy therapy (OAM yes/no), baseline BMI group (\\<25 / \\>=25 kg/m\\^2), and baseline HbA1c group.","ciNumSides":"TWO_SIDED"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Treatment comparison for HbA1c \\<=6.5% at 26 weeks between LY2189265 and placebo.","statisticalMethod":"Cochran-Mantel-Haenszel","statisticalComment":"Pairwise comparison was adjusted for prestudy therapy (OAM yes/no), baseline BMI group (\\<25 / \\>=25 kg/m\\^2), and baseline HbA1c group.","ciNumSides":"TWO_SIDED"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.844","pValueComment":"Treatment comparison for HbA1c \\<=6.5% at 26 weeks between LY2189265 and Liraglutide.","statisticalMethod":"Cochran-Mantel-Haenszel","statisticalComment":"Pairwise comparison was adjusted for prestudy therapy (OAM yes/no), baseline BMI group (\\<25 / \\>=25 kg/m\\^2), and baseline HbA1c group.","ciNumSides":"TWO_SIDED"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.112","pValueComment":"Treatment comparison for HbA1c \\<7% at 52 weeks between LY2189265 and Liraglutide.","statisticalMethod":"Cochran-Mantel-Haenszel","statisticalComment":"Pairwise comparison was adjusted for prestudy therapy (OAM yes/no), baseline BMI group (\\<25 / \\>=25 kg/m\\^2), and baseline HbA1c group.","ciNumSides":"TWO_SIDED"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.103","pValueComment":"Treatment comparison for HbA1c \\<=6.5% at 52 weeks between LY2189265 and Liraglutide.","statisticalMethod":"Cochran-Mantel-Haenszel","statisticalComment":"Pairwise comparison was adjusted for prestudy therapy (OAM yes/no), baseline BMI group (\\<25 / \\>=25 kg/m\\^2), and baseline HbA1c group.","ciNumSides":"TWO_SIDED"}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks and 52 Weeks","description":"LS means were calculated using MMRM analysis with treatment, visit, treatment-by-visit, prestudy therapy (OAM yes/no), baseline BMI group (\\<25 or \\>=25 kg/m\\^2) as fixed effects, baseline FBG as a covariate, and participant as a random effect.","populationDescription":"Participants who were randomized and received at least one dose of study medication with evaluable FBG data. Only pre-rescue measurements were used.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"milligrams per deciliter (mg/dL)","timeFrame":"Baseline, 26 weeks, 52 weeks","groups":[{"id":"OG000","title":"LY2189265","description":"Once-weekly SC injection of 0.75 mg of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG001","title":"Placebo/LY2189265","description":"Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG002","title":"Liraglutide","description":"Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"276"},{"groupId":"OG001","value":"62"},{"groupId":"OG002","value":"134"}]}],"classes":[{"title":"26 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"-39.18","spread":"1.60"},{"groupId":"OG001","value":"1.03","spread":"3.30"},{"groupId":"OG002","value":"-39.75","spread":"2.27"}]}]},{"title":"52 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"-38.93","spread":"1.72"},{"groupId":"OG001","value":"-40.93","spread":"3.62"},{"groupId":"OG002","value":"-37.15","spread":"2.47"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Treatment comparison for FBG at 26 weeks between LY2189265 and placebo.","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-40.21","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-47.31","ciUpperLimit":"-33.11"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.835","statisticalMethod":"Mixed Models Analysis","statisticalComment":"Treatment comparison for FBG at 26 weeks between LY2189265 and Liraglutide.","paramType":"LS Mean Difference","paramValue":"0.57","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.82","ciUpperLimit":"5.96"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.553","pValueComment":"Treatment comparison for FBG at 52 weeks between LY2189265 and Liraglutide.","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-1.77","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.65","ciUpperLimit":"4.10"}]},{"type":"SECONDARY","title":"Change From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) at 26 Weeks and 52 Weeks","description":"Participants were to test and record SMBG concentrations in their study diaries before each meal (breakfast, lunch, and dinner), approximately 2 hours after the start of each meal, and at bedtime. LS means were calculated using analysis of covariance (ANCOVA) model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\\<25 or \\>=25 kg/m\\^2) as fixed effects and baseline SMBG as a covariate.","populationDescription":"Participants who received at least one dose of study medication with evaluable SMBG data. Only pre-rescue measurements were used. Missing endpoints were imputed with the LOCF method, using only postbaseline data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"milligrams per deciliter (mg/dL)","timeFrame":"Baseline, 26 weeks, 52 weeks","groups":[{"id":"OG000","title":"LY2189265","description":"Once-weekly SC injection of 0.75 mg of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG001","title":"Placebo/LY2189265","description":"Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG002","title":"Liraglutide","description":"Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"277"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"133"}]}],"classes":[{"title":"Pre-morning meal, 26 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"-39.65","spread":"1.55"},{"groupId":"OG001","value":"-0.15","spread":"3.04"},{"groupId":"OG002","value":"-34.93","spread":"2.19"}]}]},{"title":"2 hours post-morning meal, 26 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"-69.64","spread":"2.80"},{"groupId":"OG001","value":"-9.29","spread":"5.48"},{"groupId":"OG002","value":"-61.67","spread":"3.96"}]}]},{"title":"Pre-midday meal, 26 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"-48.47","spread":"2.05"},{"groupId":"OG001","value":"3.91","spread":"4.03"},{"groupId":"OG002","value":"-45.08","spread":"2.91"}]}]},{"title":"2 hours post-midday meal, 26 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"-67.57","spread":"2.94"},{"groupId":"OG001","value":"-1.50","spread":"5.77"},{"groupId":"OG002","value":"-66.71","spread":"4.16"}]}]},{"title":"Pre-evening meal, 26 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"-39.64","spread":"2.15"},{"groupId":"OG001","value":"9.25","spread":"4.22"},{"groupId":"OG002","value":"-36.62","spread":"3.05"}]}]},{"title":"2 hours post-evening meal","categories":[{"measurements":[{"groupId":"OG000","value":"-56.70","spread":"2.83"},{"groupId":"OG001","value":"0.93","spread":"5.56"},{"groupId":"OG002","value":"-53.14","spread":"4.01"}]}]},{"title":"Bedtime, 26 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"-53.39","spread":"2.81"},{"groupId":"OG001","value":"4.26","spread":"5.51"},{"groupId":"OG002","value":"-51.07","spread":"3.94"}]}]},{"title":"Pre-morning meal, 52 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"-37.46","spread":"1.58"},{"groupId":"OG001","value":"-30.12","spread":"3.10"},{"groupId":"OG002","value":"-33.41","spread":"2.23"}]}]},{"title":"2 hours post-morning meal, 52 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"-66.96","spread":"2.87"},{"groupId":"OG001","value":"-65.91","spread":"5.62"},{"groupId":"OG002","value":"-60.69","spread":"4.06"}]}]},{"title":"Pre-midday meal, 52 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"-47.03","spread":"1.86"},{"groupId":"OG001","value":"-45.15","spread":"3.64"},{"groupId":"OG002","value":"-46.25","spread":"2.63"}]}]},{"title":"2 hours post-midday meal, 52 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"-68.21","spread":"2.74"},{"groupId":"OG001","value":"-58.52","spread":"5.38"},{"groupId":"OG002","value":"-62.57","spread":"3.88"}]}]},{"title":"Pre-evening meal, 52 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"-41.04","spread":"1.08"},{"groupId":"OG001","value":"-36.13","spread":"3.70"},{"groupId":"OG002","value":"-32.86","spread":"2.67"}]}]},{"title":"2 hours post-evening meal, 52 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"-55.01","spread":"2.58"},{"groupId":"OG001","value":"-55.26","spread":"5.06"},{"groupId":"OG002","value":"-42.30","spread":"3.65"}]}]},{"title":"Bedtime, 52 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"-55.76","spread":"2.39"},{"groupId":"OG001","value":"-51.19","spread":"4.69"},{"groupId":"OG002","value":"-49.10","spread":"3.35"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight at 26 Weeks and 52 Weeks","description":"LS means were calculated using MMRM analysis with treatment, visit, treatment-by-visit, prestudy therapy (OAM yes/no), baseline BMI group (\\<25 or \\>=25 kg/m\\^2) as fixed effects, baseline body weight as a covariate, and participant as a random effect.","populationDescription":"Participants who received at least one dose of study medication with evaluable body weight data. Only pre-rescue measurements were used.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kilograms (kg)","timeFrame":"Baseline, 26 weeks, 52 weeks","groups":[{"id":"OG000","title":"LY2189265","description":"Once-weekly SC injection of 0.75 mg of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG001","title":"Placebo/LY2189265","description":"Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG002","title":"Liraglutide","description":"Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"280"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"136"}]}],"classes":[{"title":"26 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.14"},{"groupId":"OG001","value":"-0.63","spread":"0.29"},{"groupId":"OG002","value":"-0.36","spread":"0.20"}]}]},{"title":"52 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":"0.18"},{"groupId":"OG001","value":"-1.03","spread":"0.37"},{"groupId":"OG002","value":"-0.13","spread":"0.26"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.057","statisticalMethod":"Mixed Models Analysis","statisticalComment":"Treatment comparison for body weight at 26 weeks between LY2189265 and placebo.","paramType":"LS Mean Difference","paramValue":"0.61","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.02","ciUpperLimit":"1.23"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.168","pValueComment":"Treatment comparison for body weight at 26 weeks between LY2189265 and Liraglutide.","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"0.34","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.14","ciUpperLimit":"0.82"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.911","pValueComment":"Treatment comparison for body weight at 52 weeks between LY2189265 and Liraglutide.","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-0.03","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.64","ciUpperLimit":"0.57"}]},{"type":"SECONDARY","title":"Change From Baseline in Insulin Sensitivity Using Updated Homeostasis Model Assessment (HOMA 2) at 26 Weeks and 52 Weeks","description":"HOMA 2 quantifies insulin resistance and beta-cell function. HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. Change in insulin sensitivity was assessed based on change from baseline of HOMA2-%S using fasting insulin (FI) and fasting C-peptide (FCP). LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\\<25 or \\>=25 kg/m\\^2) as fixed effects and baseline HOMA2-%S as a covariate.","populationDescription":"Participants who were randomized and received at least one dose of study medication with evaluable HOMA2-%S data. Only pre-rescue measurements were used. Missing endpoints were imputed with the LOCF method, using only postbaseline data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percentage of HOMA2","timeFrame":"Baseline, 26 weeks, 52 weeks","groups":[{"id":"OG000","title":"LY2189265","description":"Once-weekly SC injection of 0.75 mg of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG001","title":"Placebo/LY2189265","description":"Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG002","title":"Liraglutide","description":"Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"275"},{"groupId":"OG001","value":"62"},{"groupId":"OG002","value":"131"}]}],"classes":[{"title":"HOMA2-%S based on FI, 26 weeks (n=254, 57, 115)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.83","spread":"2.34"},{"groupId":"OG001","value":"-2.97","spread":"4.83"},{"groupId":"OG002","value":"-4.82","spread":"3.43"}]}]},{"title":"HOMA2-%S based on FCP, 26 weeks (n=275, 62, 131)","categories":[{"measurements":[{"groupId":"OG000","value":"-5.48","spread":"1.93"},{"groupId":"OG001","value":"-6.32","spread":"3.99"},{"groupId":"OG002","value":"-2.46","spread":"2.75"}]}]},{"title":"HOMA2-%S based on FI, 52 weeks (n=260, 60, 120)","categories":[{"measurements":[{"groupId":"OG000","value":"-7.75","spread":"2.34"},{"groupId":"OG001","value":"NA","spread":"NA","comment":"For ANCOVA analyses at 52 weeks, LS Means were not calculated for the Placebo/LY2189265 group as the purpose of the Week 52 analysis was to evaluate the efficacy and safety of LY2189265 compared with Liraglutide treatment for a full 52 weeks."},{"groupId":"OG002","value":"-5.26","spread":"3.38"}]}]},{"title":"HOMA2-%S based on FCP, 52 weeks (n=275, 62, 131)","categories":[{"measurements":[{"groupId":"OG000","value":"-11.72","spread":"1.88"},{"groupId":"OG001","value":"NA","spread":"NA","comment":"For ANCOVA analyses at 52 weeks, LS Means were not calculated for the Placebo/LY2189265 group as the purpose of the Week 52 analysis was to evaluate the efficacy and safety of LY2189265 compared with Liraglutide treatment for a full 52 weeks."},{"groupId":"OG002","value":"-10.68","spread":"2.68"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.723","pValueComment":"Treatment comparison for HOMA2-%S based on fasting insulin at 26 weeks between LY2189265 and placebo.","statisticalMethod":"ANCOVA","paramType":"LS Mean Difference","paramValue":"-1.86","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-12.20","ciUpperLimit":"8.48"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.998","pValueComment":"Treatment comparison for HOMA2-%S based on fasting insulin at 26 weeks between LY2189265 and Liraglutide.","statisticalMethod":"ANCOVA","paramType":"LS Mean Difference","paramValue":"-0.01","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.92","ciUpperLimit":"7.91"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.848","pValueComment":"Treatment comparison for HOMA2-%S based on fasting C-peptide at 26 weeks between LY2189265 and placebo.","statisticalMethod":"ANCOVA","paramType":"LS Mean Difference","paramValue":"0.83","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.72","ciUpperLimit":"9.38"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.357","pValueComment":"Treatment comparison for HOMA2-%S based on fasting C-peptide at 26 weeks between LY2189265 and Liraglutide.","statisticalMethod":"ANCOVA","paramType":"LS Mean Difference","paramValue":"-3.03","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.48","ciUpperLimit":"3.42"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.533","pValueComment":"Treatment comparison for HOMA2-%S based on fasting insulin at 52 weeks between LY2189265 and Liraglutide.","statisticalMethod":"ANCOVA","paramType":"LS Mean Difference","paramValue":"-2.49","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-10.35","ciUpperLimit":"5.36"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.747","pValueComment":"Treatment comparison for HOMA2-%S based on fasting C-peptide at 52 weeks between LY2189265 and Liraglutide.","statisticalMethod":"ANCOVA","paramType":"LS Mean Difference","paramValue":"-1.03","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.32","ciUpperLimit":"5.25"}]},{"type":"SECONDARY","title":"Change From Baseline in Beta-cell Function Using Updated Homeostasis Model Assessment (HOMA 2) at 26 Weeks and 52 Weeks","description":"HOMA 2 quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta-cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. Change in beta-cell function was assessed based on change from baseline of HOMA2-%B using fasting insulin (FI) and fasting C-peptide (FCP). LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\\<25 or \\>=25 kg/m\\^2) as fixed effects and baseline HOMA2-%B as a covariate.","populationDescription":"Participants who were randomized and received at least one dose of study medication with evaluable HOMA2-%B data. Only pre-rescue measurements were used. Missing endpoints were imputed with the LOCF method, using only postbaseline data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percentage of HOMA2","timeFrame":"Baseline, 26 weeks, 52 weeks","groups":[{"id":"OG000","title":"LY2189265","description":"Once-weekly SC injection of 0.75 mg of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG001","title":"Placebo/LY2189265","description":"Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG002","title":"Liraglutide","description":"Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"275"},{"groupId":"OG001","value":"62"},{"groupId":"OG002","value":"131"}]}],"classes":[{"title":"HHOMA2-%B based on FI, 26 weeks (n=254, 57, 115)","categories":[{"measurements":[{"groupId":"OG000","value":"28.42","spread":"1.54"},{"groupId":"OG001","value":"0.08","spread":"3.14"},{"groupId":"OG002","value":"25.35","spread":"2.23"}]}]},{"title":"HOMA2-%B based on FCP, 26 weeks (n=275, 62, 131)","categories":[{"measurements":[{"groupId":"OG000","value":"27.77","spread":"1.27"},{"groupId":"OG001","value":"2.94","spread":"2.61"},{"groupId":"OG002","value":"25.86","spread":"1.79"}]}]},{"title":"HOMA2-%B based on FI, 52 weeks (n=260, 60, 120)","categories":[{"measurements":[{"groupId":"OG000","value":"27.81","spread":"1.39"},{"groupId":"OG001","value":"NA","spread":"NA","comment":"For ANCOVA analyses at 52 weeks, LS Means were not calculated for the Placebo/LY2189265 group as the purpose of the Week 52 analysis was to evaluate the efficacy and safety of LY2189265 compared with Liraglutide treatment for a full 52 weeks."},{"groupId":"OG002","value":"25.89","spread":"1.99"}]}]},{"title":"HOMA2-%B based on FCP, 52 weeks (n=275, 62, 131)","categories":[{"measurements":[{"groupId":"OG000","value":"29.59","spread":"1.37"},{"groupId":"OG001","value":"NA","spread":"NA","comment":"For ANCOVA analyses at 52 weeks, LS Means were not calculated for the Placebo/LY2189265 group as the purpose of the Week 52 analysis was to evaluate the efficacy and safety of LY2189265 compared with Liraglutide treatment for a full 52 weeks."},{"groupId":"OG002","value":"28.85","spread":"1.93"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Treatment comparison for HOMA2-%B based on fasting insulin at 26 weeks between LY2189265 and placebo.","statisticalMethod":"ANCOVA","paramType":"LS Mean Difference","paramValue":"28.35","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"21.63","ciUpperLimit":"35.07"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.242","pValueComment":"Treatment comparison for HOMA2-%B based on fasting insulin at 26 weeks between LY2189265 and Liraglutide.","statisticalMethod":"ANCOVA","paramType":"LS Mean Difference","paramValue":"3.08","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.09","ciUpperLimit":"8.24"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Treatment comparison for HOMA2-%B based on fasting C-peptide at 26 weeks between LY2189265 and placebo.","statisticalMethod":"ANCOVA","paramType":"LS Mean Difference","paramValue":"24.82","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"19.25","ciUpperLimit":"30.40"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.376","pValueComment":"Treatment comparison for HOMA2-%B based on fasting C-peptide at 26 weeks between LY2189265 and Liraglutide.","statisticalMethod":"ANCOVA","paramType":"LS Mean Difference","paramValue":"1.91","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.32","ciUpperLimit":"6.13"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.417","pValueComment":"Treatment comparison for HOMA2-%B based on fasting insulin at 52 weeks between LY2189265 and Liraglutide.","statisticalMethod":"ANCOVA","paramType":"LS Mean Difference","paramValue":"1.91","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.72","ciUpperLimit":"6.54"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.753","pValueComment":"Treatment comparison for HOMA2-%B based on fasting C-peptide at 52 weeks between LY2189265 and Liraglutide.","statisticalMethod":"ANCOVA","paramType":"LS Mean Difference","paramValue":"0.73","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.83","ciUpperLimit":"5.29"}]},{"type":"SECONDARY","title":"Percentage of Participants With Hypoglycemic Episodes","description":"The percentage of participants with hypoglycemic episodes was calculated by dividing the number of participants with at least one hypoglycemic episode over the 26-week or 52-week treatment period by the total number of participants analyzed, multiplied by 100%. All classifications of hypoglycemia (documented symptomatic, asymptomatic, severe, nocturnal, non-nocturnal, probable symptomatic, relative, and unspecified) were included, except for episodes of relative hypoglycemia that were not severe. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","populationDescription":"Participants who received at least one dose of study medication.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline through 26 weeks and Baseline through 52 weeks","groups":[{"id":"OG000","title":"LY2189265","description":"Once-weekly SC injection of 0.75 mg of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG001","title":"Placebo/LY2189265","description":"Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG002","title":"Liraglutide","description":"Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"280"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"137"}]}],"classes":[{"title":"26 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"2.1"},{"groupId":"OG001","value":"1.4"},{"groupId":"OG002","value":"1.5"}]}]},{"title":"52 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"2.9"},{"groupId":"OG001","value":"2.9"},{"groupId":"OG002","value":"2.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":">0.999","pValueComment":"Treatment comparison at 26 weeks between LY2189265 and placebo.","statisticalMethod":"Fisher Exact","ciNumSides":"TWO_SIDED"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":">0.999","pValueComment":"Treatment comparison at 26 weeks between LY2189265 and Liraglutide.","statisticalMethod":"Fisher Exact","ciNumSides":"TWO_SIDED"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":">0.999","pValueComment":"Treatment comparison at 52 weeks between LY2189265 and Liraglutide.","statisticalMethod":"Fisher Exact","ciNumSides":"TWO_SIDED"}]},{"type":"SECONDARY","title":"30-Day Rate of Hypoglycemic Episodes","description":"The 30-day total hypoglycemia rate over 26 weeks and 52 weeks of treatment is summarized. All classifications of hypoglycemia (documented symptomatic, asymptomatic, severe, nocturnal, non-nocturnal, probable symptomatic, relative, and unspecified) were included, except for episodes of relative hypoglycemia that were not severe. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","populationDescription":"Participants who received at least one dose of study medication. One participant in the Liraglutide reporting group received study drug but discontinued from the study on the same day and, therefore, was not included in the analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"events per participant per 30 days","timeFrame":"Baseline through 26 weeks and Baseline through 52 weeks","groups":[{"id":"OG000","title":"LY2189265","description":"Once-weekly SC injection of 0.75 mg of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG001","title":"Placebo/LY2189265","description":"Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG002","title":"Liraglutide","description":"Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"280"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"136"}]}],"classes":[{"title":"26 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.04"},{"groupId":"OG001","value":"0.00","spread":"0.02"},{"groupId":"OG002","value":"0.00","spread":"0.02"}]}]},{"title":"52 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.02"},{"groupId":"OG001","value":"0.01","spread":"0.09"},{"groupId":"OG002","value":"0.01","spread":"0.04"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adjudicated Cardiovascular Events at 26 Weeks and 52 Weeks","description":"Deaths and nonfatal cardiovascular adverse events were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular events subjected to adjudication included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","populationDescription":"Participants who received at least one dose of study medication.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline through 26 weeks and Baseline through 52 weeks","groups":[{"id":"OG000","title":"LY2189265","description":"Once-weekly SC injection of 0.75 mg of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG001","title":"Placebo/LY2189265","description":"Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG002","title":"Liraglutide","description":"Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"280"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"137"}]}],"classes":[{"title":"26 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"52 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Pulse Rate at 26 Weeks and 52 Weeks","description":"Sitting pulse rate was measured. LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\\<25 or \\>=25 kg/m\\^2) as fixed effects and baseline pulse rate as a covariate.","populationDescription":"Participants who were randomized and received at least one dose of study medication with evaluable pulse rate data. Only pre-rescue measurements were used. LOCF was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"beats per minute (bpm)","timeFrame":"Baseline, 26 weeks, 52 weeks","groups":[{"id":"OG000","title":"LY2189265","description":"Once-weekly SC injection of 0.75 mg of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG001","title":"Placebo/LY2189265","description":"Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG002","title":"Liraglutide","description":"Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"280"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"136"}]}],"classes":[{"title":"26 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"3.35","spread":"0.45"},{"groupId":"OG001","value":"1.49","spread":"0.90"},{"groupId":"OG002","value":"4.77","spread":"0.64"}]}]},{"title":"52 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"3.11","spread":"0.42"},{"groupId":"OG001","value":"4.42","spread":"0.86"},{"groupId":"OG002","value":"5.13","spread":"0.60"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Blood Pressure at 26 Weeks and 52 Weeks","description":"Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\\<25 or \\>=25 kg/m\\^2) as fixed effects and baseline blood pressure as a covariate.","populationDescription":"Participants who were randomized and received at least one dose of study medication with evaluable blood pressure data. Only pre-rescue measurements were used. LOCF was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"milliliters of mercury (mmHG)","timeFrame":"Baseline, 26 weeks, 52 weeks","groups":[{"id":"OG000","title":"LY2189265","description":"Once-weekly SC injection of 0.75 mg of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG001","title":"Placebo/LY2189265","description":"Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG002","title":"Liraglutide","description":"Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"280"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"136"}]}],"classes":[{"title":"SBP, 26 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"0.62","spread":"0.62"},{"groupId":"OG001","value":"0.53","spread":"1.25"},{"groupId":"OG002","value":"-2.10","spread":"0.89"}]}]},{"title":"DBP, 26 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"1.09","spread":"0.39"},{"groupId":"OG001","value":"0.29","spread":"0.78"},{"groupId":"OG002","value":"0.43","spread":"0.56"}]}]},{"title":"SBP, 52 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"1.32","spread":"0.66"},{"groupId":"OG001","value":"0.37","spread":"1.37"},{"groupId":"OG002","value":"-1.86","spread":"0.95"}]}]},{"title":"DBP, 52 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"1.41","spread":"0.41"},{"groupId":"OG001","value":"1.16","spread":"0.86"},{"groupId":"OG002","value":"1.17","spread":"0.60"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adjudicated Pancreatitis at 26 Weeks and 52 Weeks","description":"Events of pancreatitis (including suspected pancreatitis and severe or serious abdominal pain) were adjudicated by a committee of expert physicians external to the Sponsor. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","populationDescription":"Participants who received at least one dose of study medication.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline through 26 weeks and Baseline through 52 weeks","groups":[{"id":"OG000","title":"LY2189265","description":"Once-weekly SC injection of 0.75 mg of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG001","title":"Placebo/LY2189265","description":"Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG002","title":"Liraglutide","description":"Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"280"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"137"}]}],"classes":[{"title":"26 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"52 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Pancreatic Enzymes at 26 Weeks and 52 Weeks","description":"Pancreatic enzyme (lipase and total amylase) concentrations were measured.","populationDescription":"Participants who were randomized and received at least one dose of study medication with evaluable pancreatic enzyme data. Only pre-rescue measurements were used. LOCF was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"units/liter","timeFrame":"Baseline, 26 weeks, 52 weeks","groups":[{"id":"OG000","title":"LY2189265","description":"Once-weekly SC injection of 0.75 mg of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG001","title":"Placebo/LY2189265","description":"Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG002","title":"Liraglutide","description":"Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"275"},{"groupId":"OG001","value":"65"},{"groupId":"OG002","value":"131"}]}],"classes":[{"title":"Lipase, 26 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"7.0","lowerLimit":"1.0","upperLimit":"13.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"-6.0","upperLimit":"5.0"},{"groupId":"OG002","value":"11.0","lowerLimit":"5.0","upperLimit":"21.0"}]}]},{"title":"Total Amylase, 26 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"7.0","lowerLimit":"2.0","upperLimit":"15.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"-6.0","upperLimit":"6.0"},{"groupId":"OG002","value":"7.0","lowerLimit":"1.0","upperLimit":"15.0"}]}]},{"title":"Lipase, 52 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"6.0","lowerLimit":"1.0","upperLimit":"12.0"},{"groupId":"OG001","value":"6.0","lowerLimit":"2.0","upperLimit":"12.0"},{"groupId":"OG002","value":"9.0","lowerLimit":"3.0","upperLimit":"19.0"}]}]},{"title":"Total Amylase, 52 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"7.0","lowerLimit":"1.0","upperLimit":"14.0"},{"groupId":"OG001","value":"9.0","lowerLimit":"3.0","upperLimit":"14.0"},{"groupId":"OG002","value":"6.0","lowerLimit":"1.0","upperLimit":"11.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Calcitonin at 26 Weeks and 52 Weeks","populationDescription":"Participants who were randomized and received at least one dose of study medication with evaluable serum calcitonin data. Only pre-rescue measurements were used. LOCF was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"picograms/milliliter","timeFrame":"Baseline, 26 weeks, 52 weeks","groups":[{"id":"OG000","title":"LY2189265","description":"Once-weekly SC injection of 0.75 mg of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG001","title":"Placebo/LY2189265","description":"Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG002","title":"Liraglutide","description":"Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"274"},{"groupId":"OG001","value":"65"},{"groupId":"OG002","value":"131"}]}],"classes":[{"title":"26 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.0"},{"groupId":"OG002","value":"0.0","lowerLimit":"0.0","upperLimit":"0.0"}]}]},{"title":"52 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.0"},{"groupId":"OG002","value":"0.0","lowerLimit":"0.0","upperLimit":"0.0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent LY2189265 Anti-Drug Antibodies (ADAs) at 26 Weeks and 52 Weeks","description":"A participant was considered to have treatment-emergent LY2189265 ADAs if the participant had at least 1 titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from the baseline measurement.","populationDescription":"Participants who received at least one dose of study medication and had LY2189265 evaluable ADA data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline through 26 weeks and Baseline through 52 weeks","groups":[{"id":"OG000","title":"LY2189265","description":"Once-weekly SC injection of 0.75 mg of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG001","title":"Placebo/LY2189265","description":"Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG002","title":"Liraglutide","description":"Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"134"}]}],"classes":[{"title":"26 weeks (n=279, 68, 133)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"52 weeks (n=279, 68, 134)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Requiring Additional Intervention Due to Hyperglycemia at 26 Weeks and 52 Weeks","description":"Additional intervention was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. The number of participants requiring additional intervention due to hyperglycemia is summarized cumulatively at 26 and 52 weeks.","populationDescription":"Participants who received at least one dose of study medication.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline through 26 weeks and Baseline through 52 weeks","groups":[{"id":"OG000","title":"LY2189265","description":"Once-weekly SC injection of 0.75 mg of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG001","title":"Placebo/LY2189265","description":"Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG002","title":"Liraglutide","description":"Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"280"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"137"}]}],"classes":[{"title":"26 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"52 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Electrocardiogram Parameters at 26 Weeks and 52 Weeks","description":"Fridericia Corrected QT (QTcF) Interval and PR Interval are summarized. The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTcF = QT/RR\\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. LS means were calculated using ANCOVA model with treatment as a fixed effect and the baseline ECG parameter as the covariate.","populationDescription":"Participants who were randomized and received at least one dose of study medication with evaluable ECG data. Only pre-rescue measurements were used. LOCF was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"milliseconds (msec)","timeFrame":"Baseline, 26 weeks, 52 weeks","groups":[{"id":"OG000","title":"LY2189265","description":"Once-weekly SC injection of 0.75 mg of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG001","title":"Placebo/LY2189265","description":"Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy."},{"id":"OG002","title":"Liraglutide","description":"Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"274"},{"groupId":"OG001","value":"65"},{"groupId":"OG002","value":"128"}]}],"classes":[{"title":"QTcF, 26 weeks (n=273, 64, 128)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.02","spread":"0.70"},{"groupId":"OG001","value":"-0.96","spread":"1.44"},{"groupId":"OG002","value":"-1.89","spread":"1.02"}]}]},{"title":"QTcF, 52 weeks (n=274, 64, 128)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.76","spread":"0.68"},{"groupId":"OG001","value":"-0.80","spread":"1.41"},{"groupId":"OG002","value":"-4.35","spread":"1.00"}]}]},{"title":"PR, 26 weeks (n=269, 65, 126)","categories":[{"measurements":[{"groupId":"OG000","value":"2.20","spread":"0.60"},{"groupId":"OG001","value":"-0.45","spread":"1.22"},{"groupId":"OG002","value":"2.07","spread":"0.88"}]}]},{"title":"PR, 52 weeks (n=270, 65, 126)","categories":[{"measurements":[{"groupId":"OG000","value":"2.81","spread":"0.82"},{"groupId":"OG001","value":"2.60","spread":"1.33"},{"groupId":"OG002","value":"3.71","spread":"1.03"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","eventGroups":[{"id":"EG000","title":"LY2189265","description":"Once-weekly SC injection of 0.75 mg of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.","seriousNumAffected":9,"seriousNumAtRisk":280,"otherNumAffected":182,"otherNumAtRisk":280},{"id":"EG001","title":"Placebo/LY2189265","description":"Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.","seriousNumAffected":5,"seriousNumAtRisk":70,"otherNumAffected":53,"otherNumAtRisk":70},{"id":"EG002","title":"Liraglutide","description":"Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy.","seriousNumAffected":7,"seriousNumAtRisk":137,"otherNumAffected":94,"otherNumAtRisk":137}],"seriousEvents":[{"term":"Eosinophilia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Sudden hearing loss","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Large intestine polyp","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Bile duct stone","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Bacterial infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Hiv infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Pneumocystis jirovecii pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Hand fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Lumbar spinal stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Rotator cuff syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Colon cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Invasive ductal breast carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Lung adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Ovarian cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Pancreatic carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Prostate cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":228},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":113}]},{"term":"Intracranial aneurysm","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Anaemia macrocytic","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Ventricular extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Deafness neurosensory","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Ear pain","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Eustachian tube obstruction","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Goitre","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Asthenopia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Conjunctivitis allergic","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Diabetic retinopathy","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":137}]},{"term":"Dry eye","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Eyelid oedema","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Glaucoma","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Iritis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Keratitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Macular oedema","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Pingueculitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Retinal tear","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Vitreous floaters","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Vitreous haemorrhage","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":137}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":137}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":280},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":280},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":137}]},{"term":"Abnormal faeces","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Anal fistula","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":22,"numAtRisk":280},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":70},{"groupId":"EG002","numEvents":11,"numAffected":11,"numAtRisk":137}]},{"term":"Dental caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":280},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":70},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":137}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":20,"numAtRisk":280},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":70},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":137}]},{"term":"Diverticulum intestinal","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Dyschezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":137}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Epigastric discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Eructation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":137}]},{"term":"Gastric disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Gastric polyps","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":137}]},{"term":"Gastritis atrophic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Gastritis erosive","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Gastroduodenal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":137}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Hiatus hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Hyperchlorhydria","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Large intestine polyp","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":137}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":17,"numAtRisk":280},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG002","numEvents":18,"numAffected":11,"numAtRisk":137}]},{"term":"Periodontal disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Radicular cyst","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":137}]},{"term":"Application site haematoma","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":137}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Device failure","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Early satiety","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":137}]},{"term":"Feeling abnormal","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Induration","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Injection site bruising","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Injection site dermatitis","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":137}]},{"term":"Injection site haemorrhage","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Injection site induration","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Injection site pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":137}]},{"term":"Injection site rash","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Injection site reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Local swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Thirst","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Xerosis","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Alcoholic liver disease","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Gallbladder polyp","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Hepatic cyst","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Hepatic steatosis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":137}]},{"term":"Hyperplastic cholecystopathy","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Seasonal allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Acute sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Anisakiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Body tinea","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":280},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":137}]},{"term":"Bronchitis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Candida infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Chronic sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Dermatitis infected","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Enteritis infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Fungal skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Gingivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Helicobacter gastritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Helicobacter infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Herpes virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Hordeolum","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":70},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":137}]},{"term":"Intervertebral discitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":61,"numAffected":52,"numAtRisk":280},{"groupId":"EG001","numEvents":12,"numAffected":7,"numAtRisk":70},{"groupId":"EG002","numEvents":34,"numAffected":24,"numAtRisk":137}]},{"term":"Oral herpes","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Otitis externa","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Otitis media","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Parotitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Periodontitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":137}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":280},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":70},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":137}]},{"term":"Pharyngitis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Pyoderma","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Sialoadenitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Tinea infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Tinea pedis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":137}]},{"term":"Tooth abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Arthropod bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":3,"numAffected":1,"numAtRisk":137}]},{"term":"Arthropod sting","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Chillblains","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":137}]},{"term":"Epicondylitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Excoriation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Fibula fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Hand fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Ligament sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Limb crushing injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Limb injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Meniscus injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Muscle strain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":137}]},{"term":"Post-traumatic neck syndrome","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Scratch","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Stress fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Subdural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Sunburn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Thermal burn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Arteriogram coronary","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":137}]},{"term":"Blood triglycerides increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Blood uric acid increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Blood urine present","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Crystal urine present","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Electrocardiogram t wave abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":280},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":137}]},{"term":"Liver function test abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Monocyte count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Occult blood positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Pancreatic enzymes increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Prostatic specific antigen increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":228},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":113}]},{"term":"Skin test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Transaminases increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Urine albumin/creatinine ratio increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":137}]},{"term":"Dyslipidaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":137}]},{"term":"Gout","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Hyperamylasaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Hyperlipidaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":280},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":70},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":137}]},{"term":"Cervical spinal stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Lumbar spinal stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Muscle fatigue","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Musculoskeletal stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":137}]},{"term":"Myositis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Osteitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Osteoporosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Periarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Spinal osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Tendonitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Tenosynovitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Trigger finger","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Colon cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Duodenal neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Meningioma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Skin papilloma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Thyroid neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Uterine leiomyoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":52},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Autonomic nervous system imbalance","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Autonomic neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Carotid arteriosclerosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Cervical radiculopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Cervicobrachial syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Diabetic neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":137}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Dizziness exertional","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Head discomfort","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":137}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Intercostal neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Lacunar infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Radial nerve palsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":137}]},{"term":"Anxiety disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Irritability","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Sleep disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Calculus ureteric","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Calculus urinary","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Cystitis noninfective","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Diabetic nephropathy","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Hypertonic bladder","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":137}]},{"term":"Renal cyst","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Benign prostatic hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":228},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":113}]},{"term":"Calculus prostatic","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":228},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":113}]},{"term":"Cystocele","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Erectile dysfunction","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":228},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":113}]},{"term":"Metrorrhagia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":52},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Prostatitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":228},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":113}]},{"term":"Prostatomegaly","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":228},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":113}]},{"term":"Rectocele","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":52},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Vulvovaginal pruritus","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":52},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Hyperventilation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Oropharyngeal discomfort","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Rhinitis allergic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":137}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Upper respiratory tract inflammation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":4,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":137}]},{"term":"Vasomotor rhinitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Acne","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Alopecia areata","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":137}]},{"term":"Dermal cyst","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Dermatitis contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Drug eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Haemorrhage subcutaneous","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Hyperkeratosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Miliaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":280},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":70},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":137}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":137}]},{"term":"Skin exfoliation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Skin mass","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":137}]},{"term":"Denture wearer","organSystem":"Social circumstances","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Dental care","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Dental prosthesis placement","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Intra-cerebral aneurysm operation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Large intestinal polypectomy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Limb operation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Photocoagulation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Retinal laser coagulation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Tooth extraction","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":137}]},{"term":"Tooth repair","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":280},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":137}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 17.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":137}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D003924","term":"Diabetes Mellitus, Type 2"}],"ancestors":[{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C555680","term":"dulaglutide"},{"id":"D000069450","term":"Liraglutide"}],"ancestors":[{"id":"D052216","term":"Glucagon-Like Peptide 1"},{"id":"D004763","term":"Glucagon-Like Peptides"},{"id":"D052336","term":"Proglucagon"},{"id":"D005768","term":"Gastrointestinal Hormones"},{"id":"D006728","term":"Hormones"},{"id":"D006730","term":"Hormones, Hormone Substitutes, and Hormone Antagonists"}]}},"hasResults":true}